Close Menu

NEW YORK – Avellino Labs on March 25 received Emergency Use Authorization for its coronavirus real-time PCR diagnostic test from the US Food and Drug Administration.

The assay, called AvellinoCoV2 test, is designed for the detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19, from nasopharyngeal and oropharyngeal swab specimens from individuals suspected by their healthcare provider of being infected with the virus.

According to the EUA, the test may only be performed by Avellino's CLIA laboratory. The company is based in Menlo Park, California.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.